Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H21NO4 |
Molecular Weight | 219.278 |
Optical Activity | ( - ) |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO
InChI
InChIKey=UQRORFVVSGFNRO-XFWSIPNHSA-N
InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9+,10-/m1/s1
Molecular Formula | C10H21NO4 |
Molecular Weight | 219.278 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03425539
Phase 3 study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) b.i.d.; dose adjusted for renal function.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:40:57 GMT 2023
by
admin
on
Sat Dec 16 01:40:57 GMT 2023
|
Record UNII |
GVS3YDM418
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
495815
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/12/1033
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID60161601
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
PRIMARY | |||
|
100000177224
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
PRIMARY | |||
|
9539
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
PRIMARY | |||
|
DB14872
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
PRIMARY | |||
|
501391
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
PRIMARY | |||
|
GVS3YDM418
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
PRIMARY | |||
|
GH-14
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
PRIMARY | |||
|
141206-42-0
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
PRIMARY | |||
|
C170135
Created by
admin on Sat Dec 16 01:40:57 GMT 2023 , Edited by admin on Sat Dec 16 01:40:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|